|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
P I3 K inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2014
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Zydelig
|
|
gptkbp:clinical_trial
|
Phase 1
combination therapy
Phase 2
Phase 3
monotherapy
|
|
gptkbp:contraindication
|
severe liver impairment
active infection
|
|
gptkbp:discovered_by
|
gptkb:Gilead_Sciences
|
|
gptkbp:dissolved
|
soluble in DMSO
slightly soluble in water
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:excretion
|
biliary
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
idelalisib
|
|
gptkbp:indication
|
relapsed CLL
relapsed FL
|
|
gptkbp:ingredients
|
C22 H23 Cl N2 O4 S
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:invention
|
2029
patented
|
|
gptkbp:is_atype_of
|
L01 X X40
|
|
gptkbp:is_available_in
|
gptkb:legislation
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
follicular lymphoma
|
|
gptkbp:lifespan
|
approximately 8 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:Gilead_Sciences
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:monitors
|
0 A0 B1 F1 D5 H
|
|
gptkbp:research_areas
|
oncology
hematology
|
|
gptkbp:safety_features
|
risk of serious infections
risk of intestinal perforation
risk of pneumonitis
risk of severe liver toxicity
|
|
gptkbp:side_effect
|
diarrhea
hepatotoxicity
neutropenia
pneumonitis
|
|
gptkbp:targets
|
P I3 K delta
|
|
gptkbp:type_of
|
870281-82-6
|
|
gptkbp:weight
|
438.94 g/mol
|
|
gptkbp:bfsParent
|
gptkb:Calquence
|
|
gptkbp:bfsLayer
|
4
|